Drugs / PSI-697
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03860506 | Apr → Jul 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00367692 | Sep 2006 → Apr 2007 | scleritis | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSI-697 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03860506 ↗ |
| Modality | Small molecule | — CHEMBL219046 ↗ |
| Route | Oral | “Orally Administered PSI-697” NCT00367692 ↗ |